1WHO handbook for reporting results of cancer treatment . Geneva (Switzerland): World Health Organization Offset Publication No.1979;48
2Salni, S. Radiologic Measurement of Tumor Size in Clinical Trials:Past, Present, and Future. AJR, 2001; 176:333 - 334
3Ross, B.D, Moffat, etal. Evaluation of Cancer Therapy UsingDiffusion Magnetic Resonance Imaging. Mol Cancer Ther, 2003; 2:581 -587
4Fox, E, Curt, G. A, et al. Clinical Trial Design for Target-Based Therapy. Oncologist, 2002;7:401 - 409
5Schwartz, L. H. Mazumdar. Brown. Variability in Response Assessment in Solid Tumors: Effect of Number of Lesions Chosen for Measurement. Clin Cancer Res, 2003;9:4318-4323
6Park, J.O, Lee, et al. Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria. Jpn. J Clin. Oncol,2003; 33: 533 - 537
7Gehan, E. A, Tefft, M.C. Will There Be Resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst,2000;92:179 - 181
8Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981;47:207-214
9Warr D, McKinney S, Tannock I. Influence of measurement error on response rates, Cancer Treat Reg, 1985;69:1127- 1130
10C, ehen. M Schneideremann. Historial and methodological developments in clinical trail at the national cancer institute. Stat Med, 1990;9:871- 880
